alpha-Fucose-mediated binding and degradation of tissue-type plasminogen activator by HepG2 cells
- PMID: 8113404
- PMCID: PMC293905
- DOI: 10.1172/JCI117023
alpha-Fucose-mediated binding and degradation of tissue-type plasminogen activator by HepG2 cells
Abstract
The glycoprotein tissue-type plasminogen activator (t-PA) is subject to hepatic clearance in humans. Here, the interaction of t-PA with a well-differentiated hepatoma cell line (HepG2) was examined. Suspended HepG2 cells bound 125I-t-PA in a specific, saturable, and reversible fashion through a Ca(2+)-dependent, active site-independent mechanism. Binding isotherms indicated a high affinity system with a single class of saturable binding sites (Kd 39 nM; maximum binding capacity 493,000 sites per cell). Bound t-PA was rapidly degraded at 37 degrees C in a manner inhibited by lysosomotropic agents or metabolic inhibitors. Pretreatment of t-PA with monoclonal antibodies against the EGF/fibronectin finger domain, but not kringle 2 or kringle 1, reduced total binding by 86%. Binding of 125I-t-PA to HepG2 cells was inhibited by monosaccharides fucose and galactose and by the neoglycoprotein fucosyl-albumin. Enzymatic removal of alpha-fucose residues, but not alpha-galactose, high mannose, or complex oligosaccharide from 125I-t-PA, reduced specific binding by 60 +/- 5%. Binding was also inhibited by high, but not low, molecular weight urokinase, which contains an EGF-based threonine-linked alpha-fucose homologous to that of t-PA. These data suggest that EGF-associated O-linked alpha-fucose may mediate t-PA binding and degradation by HepG2 cells. This mechanism may be relevant to other proteins with analogous structures.
Comment in
-
Tissue-type plasminogen activator: a role for O-linked fucose.J Clin Invest. 1994 Feb;93(2):459. doi: 10.1172/JCI116991. J Clin Invest. 1994. PMID: 8113382 Free PMC article. No abstract available.
Similar articles
-
Identification and partial characterization by chemical cross-linking of a binding protein for tissue-type plasminogen activator (t-PA) on rat hepatoma cells. A plasminogen activator inhibitor type 1-independent t-PA receptor.J Biol Chem. 1992 Aug 5;267(22):15595-602. J Biol Chem. 1992. PMID: 1322401
-
Identification of determinants involved in binding of tissue-type plasminogen activator-plasminogen activator inhibitor type 1 complexes to HepG2 cells.J Biol Chem. 1990 Aug 25;265(24):14093-9. J Biol Chem. 1990. PMID: 2167306
-
Receptor-mediated endocytosis of tissue-type plasminogen activator by low density lipoprotein receptor-related protein on human hepatoma HepG2 cells.J Biol Chem. 1993 Jun 15;268(17):13002-9. J Biol Chem. 1993. PMID: 8389767
-
Characterization of the interaction both in vitro and in vivo of tissue-type plasminogen activator (t-PA) with rat liver cells. Effects of monoclonal antibodies to t-PA.Biochem J. 1992 Jun 1;284 ( Pt 2)(Pt 2):545-50. doi: 10.1042/bj2840545. Biochem J. 1992. PMID: 1318035 Free PMC article.
-
Receptor-mediated endocytosis of tissue-type plasminogen activator (t-PA) by liver cells.Thromb Res Suppl. 1990;10:63-71. doi: 10.1016/0049-3848(90)90379-q. Thromb Res Suppl. 1990. PMID: 2107599 Review.
Cited by
-
Scale up and pharmacokinetic study of a novel mutated chimeric tissue plasminogen activator (mt-PA) in rats.Sci Rep. 2017 Feb 22;7:43028. doi: 10.1038/srep43028. Sci Rep. 2017. PMID: 28223717 Free PMC article.
-
Impacts of tissue-type plasminogen activator (tPA) on neuronal survival.Front Cell Neurosci. 2015 Oct 16;9:415. doi: 10.3389/fncel.2015.00415. eCollection 2015. Front Cell Neurosci. 2015. PMID: 26528141 Free PMC article. Review.
-
Two receptor systems are involved in the plasma clearance of tissue-type plasminogen activator (t-PA) in vivo.J Clin Invest. 1995 Aug;96(2):1164-8. doi: 10.1172/JCI118105. J Clin Invest. 1995. PMID: 7635954 Free PMC article.
-
Interaction of mutants of tissue-type plasminogen activator with liver cells: effect of domain deletions.Biochem J. 1996 Feb 1;313 ( Pt 3)(Pt 3):775-80. doi: 10.1042/bj3130775. Biochem J. 1996. PMID: 8611154 Free PMC article.
-
Reteplase versus alteplase for acute ischaemic stroke within 4.5 hours (RAISE): rationale and design of a multicentre, prospective, randomised, open-label, blinded-endpoint, controlled phase 3 non-inferiority trial.Stroke Vasc Neurol. 2024 Nov 5;9(5):568-573. doi: 10.1136/svn-2023-003035. Stroke Vasc Neurol. 2024. PMID: 38286482 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous